121 related articles for article (PubMed ID: 28643748)
21. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL.
Li XM; Zhang L; Li J; Li Y; Wang HL; Ji GY; Kuwahara M; Zhao XJ
Asian J Androl; 2005 Sep; 7(3):323-8. PubMed ID: 16110361
[TBL] [Abstract][Full Text] [Related]
22. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
[TBL] [Abstract][Full Text] [Related]
23. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
Han G; Gao JP; Cao XL; Hong BF; Tang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
[TBL] [Abstract][Full Text] [Related]
24. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
25. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
[TBL] [Abstract][Full Text] [Related]
26. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population.
Mungan AG; Erol B; Akduman B; Bozdogan G; Kiran S; Yesilli C; Mungan NA
Clin Chem Lab Med; 2007; 45(7):912-6. PubMed ID: 17617037
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
28. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
30. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
31. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation.
Stephan C; Jung K; Cammann H; Vogel B; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Lein M; Schnorr D; Sinha P; Loening SA
Int J Cancer; 2002 May; 99(3):466-73. PubMed ID: 11992419
[TBL] [Abstract][Full Text] [Related]
32. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
33. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
34. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
35. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
[TBL] [Abstract][Full Text] [Related]
36. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer.
Mettlin C; Chesley AE; Murphy GP; Bartsch G; Toi A; Bahnson R; Church P
Prostate; 1999 May; 39(3):153-8. PubMed ID: 10334103
[TBL] [Abstract][Full Text] [Related]
37. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
[TBL] [Abstract][Full Text] [Related]
38. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
[TBL] [Abstract][Full Text] [Related]
39. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Sokoll LJ; Chan DW; Mikolajczyk SD; Rittenhouse HG; Evans CL; Linton HJ; Mangold LA; Mohr P; Bartsch G; Klocker H; Horninger W; Partin AW
Urology; 2003 Feb; 61(2):274-6. PubMed ID: 12597929
[TBL] [Abstract][Full Text] [Related]
40. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
